Ischemic preconditioning (IP) is gaining popularity as a pre-exercise intervention to provide acute meaningful improvements in competitive sporting performance. Although the effect of IP is still debated, a typical exercise IP protocol subjects the local musculature to 4 × 5 min ischemia followed by 5 min of reperfusion [@R02-2018-0071-0026] . A single exposure to IP has shown positive benefits on aerobic and anaerobic exercise [@R02-2018-0071-0028] , but unclear effects with regard to improving sprint and power-based performance [@R02-2018-0071-0028] and no improvement over placebo in resistance exercise repetition performance [@R02-2018-0071-0021] [@R02-2018-0071-0022] or recreational sprint swimming [@R02-2018-0071-0020] . A recent systematic review by Incognito and colleagues (2016) concludes that "although, large between-study variability exists, the most consistent benefit of IP is for an improvement in time trial performance in exercise tests of predominantly lactic anaerobic and aerobic capacity" [@R02-2018-0071-0014] . Similarly, a meta-analysis by Salvador et al. (2016) calculates IP to have a small beneficial effect (ES=0.43; 90% CI, 0.28--0.51) on performance and that IP had a \>99% and \~58% chance of benefiting aerobic and anaerobic exercise, respectively [@R02-2018-0071-0028] . In terms of the magnitude of improvement, during 5-km cycling time-trial performances Paradis-Deschenes et al. (2017) noted a 1.1% and 1.5% improvement at low and moderate altitudes, respectively [@R02-2018-0071-0025] .

Despite the popularity of a singular application of IP, the effect of daily repeated ischemia-reperfusion has only recently been investigated. Using a randomized cross-over trial, Foster et al. (2014) investigated the prophylactic use of IP administered daily over 5 days and found improved oxygen saturations following ascent to high altitude [@R02-2018-0071-0010] . Similarly, 7 days of IP application improved flow-mediated dilation and resting skin microcirculation and these beneficial effects remain present for at least 7 days after the cessation of the IP stimulus [@R02-2018-0071-0016] .

In an exercise context, one recent study by Banks et al. (2016) with 9 days of IP failed to show any improvement in aerobic capacity during a progressive ramp bicycle test conducted at least 24 h after the final IP application [@R02-2018-0071-0002] . However, another study using 7 days of IP resulted in significant improvements in maximal oxygen consumption (VO ~2~ max) and maximum aerobic power in untrained individuals [@R02-2018-0071-0019] , and it was also shown that aerobic capacity continued to increase seven days following the cessation of treatment, which is similar to that shown in endothelial function and microcirculation [@R02-2018-0071-0016] . Moreover, the amount of ischemia-reperfusion tissue exposure area and time required to elicit these changes were similar to the majority of exercise-related research (4×5 min).

Repeating the IP
================

Coaches and athletes are interested in the optimal IP dose to maximize exercise capacity and sport-specific performance. Recently a dose comparison study confirmed the traditional (4×5 min) protocol was superior for improving endurance performance when compared to a doubling of the ischemia-reperfusion-induced cellular stress (8×5 min) within the same session [@R02-2018-0071-0006] . This leads to the question of whether increasing the cellular stress through a combination of daily application and an increased daily frequency of application would prove more successful.

Within medicine there is emerging evidence for a dose dependency of daily IP application on clinical outcomes [@R02-2018-0071-0016] . This research intends to explore dose dependency in the sporting context. We measured several aerobic capacity parameters during a simulated 4000-m cycling time-trial time with the intention of elucidating any potential added benefit of doubling the ischemia-reperfusion tissue exposure in moderately trained cyclists. Our hypothesis was that seven days of a twice-a-day alternating-leg unilateral repeated IP protocol would provide enhanced aerobic capacity and sport-specific benefit over a once-a-day repeated IP protocol.

Materials and Methods
=====================

Subjects Twenty-six age-group track cyclists competing at the national level in their respective categories volunteered for the study. Two withdrew for different reasons resulting in 24 (13 men and 11 women) being included in the full analysis. The inclusion criteria were track cycling athletes who were currently competing nationally in their respective age group. Athletes who had previously undergone surgery to alleviate iliac artery endofibrosis were excluded from the study as a precaution to the reperfusion-based protocol and pressure cuff placement, as well as any athlete who was currently taking or had taken creatine or beta-alanine supplements in the previous four weeks. We confirm that our study meets the ethical standards of the Sports Medicine International Open journal [@R02-2018-0071-0012] . The experimental protocol was approved by the University of Canterbury Human Ethics Committee (approval number HEC 2015/78) and all athletes were informed of the risks involved in the study before their written consent was obtained.

Study design
------------

We conducted a randomized, sham-controlled, single (athlete) blinded experiment to evaluate the effects of repeated IP dose-dependence on cycling aerobic capacity and performance ( [Fig. 1](#FI02-2018-0071-0001){ref-type="fig"} ). All athletes were competing at the national age-group level and were accustomed to the specific testing protocols of the study, meaning no familiarization of the testing procedures was necessary. Upon reporting to the lab, athletes had their height measured with a wall-mounted stadiometer (Seca, Hamburg, Germany) and body mass recorded (inBody270, Seoul, Korea) before undertaking a 4000-m cycling time trial. Following the completion of this first 4000-m time trial, athletes were randomly assigned to either once-a-day or twice-a-day or sham IP protocols. Randomization was achieved by ranking and matching athletes based on their VO ~2~ peak and using a coin toss to allocate into groups with their characteristics provided in [Table 1](#TB02-2018-0071-0001){ref-type="table"} . Although athletes were likely aware of pressure differences between conditions, they remained naïve to the rationale of the experiment. At the completion of the first testing day, each athlete was required to complete one of three repeated IP protocols for the next seven consecutive days before returning the following Sunday to complete the same testing procedure. This was followed by seven days of no IP treatment before repeating the test for a final time.

![Experimental design](10-1055-a-0639-5035-i02-2018-0071-0001){#FI02-2018-0071-0001}

###### 

**Table 1** Subject characteristics. Data is presented as mean±SD.

                                        Sham (n=8)         Once-a-day (n=8)   Twice-a-day (n=8)
  ------------------------------------- ------------------ ------------------ -------------------
  Age (years)                           41.0±10.1          36.0±17.9          36.0±10.3
  Height (cm)                           170.4±10.4         173.6±6.7          177.6±7.9
  Weight (kg)                           70.6±6.9           72.7±13.7          82.2±13.8
  VO ~2~ peak (ml.min ^−1^ .kg ^−1^ )   45.8±13.9          49.5±8.8           51.1±10.9
  Training hours per week               13.7±7.1           11.3±3.9           10.4±8.9
  Training phase                        Strength/aerobic   Strength/aerobic   Strength/aerobic

Testing procedures
------------------

### 4000-m cycling-ergometer time trials

The experimental protocol required athletes to complete a 4000-m cycling-ergometer time trial with re-testing completed a week and a fortnight later. For logistical reasons the athletes were tested in the same order, each individual was tested at approximately the same time of day, and all athletes performed the time trial alone.

Athletes were instructed to refrain from any form of strenuous or prolonged exercise, caffeine, supplements (sodium bicarbonate) and alcohol for at least 24 h prior to testing. They were asked to remain in a euhydrated state and to adhere to their normal diet and training regimes or activities throughout the two weeks of testing. There was no effort to control diet or training, although each athlete was asked to provide a training diary for the study duration. Data collection was undertaken at the beginning of the track season; hence the subjects were all completing a strength/aerobic phase as indicated in [Table 1](#TB02-2018-0071-0001){ref-type="table"} .

The 4000-m cycling time trial is considered the pinnacle of aerobic track-cycling performance. It consists of a self-pacing strategy that predominantly utilizes aerobic energy systems except for a greater (10%) anaerobic contribution at the beginning and end of the effort [@R02-2018-0071-0031] . Most importantly, it offers a reliable platform for assessing aerobic capacity considering trained cyclists use a highly consistent pacing strategy [@R02-2018-0071-0031] . Athletes were required to complete their traditional warm-up strategy on a Monark ergometer (Ergomedic 894E, Monark, Vansbro, Sweden) that replicated their competition preparation on each of the three occasions. The 4000-m time trial was completed on a Velotron Dynafit cycle ergometer (Racermate, Seattle, WA, USA) which has been shown to produce consistent indices of power during exercise [@R02-2018-0071-0030] . Before each test commenced, factory calibration was verified using the Accuwatt "run down" verification program (RacerMate, Seattle, WA, USA). Each athlete had the ergometer specifically adjusted to replicate their own bike, which included their own pedals. The settings, which included crank length, seat height, top tube length, handle bar height and bottom bracket distance, were recorded and replicated on each occasion. At the completion of the warm-up, athletes were given 5 mins to relax before completing the flat 4000-m time-trial profile using the provided software (Racermate, Seattle, WA, USA). No visual feedback or verbal encouragement was provided except for verbal feedback every 250 m to replicate an indoor 250-m velodrome setting. Athletes were instructed to complete the 4000 m in the quickest time possible using a pre-selected gear (same on each occasion) that they would typically utilize in competition. The tests were completed in the seated position except for the beginning of the test, when athletes could get out of the seat until on top of the gear.

Respiratory gas exchange
------------------------

Each athlete's respiratory gas exchange parameters were measured throughout the 4000-m time trial using a Cortex Metalyser 3B (Biophysik, Leipzig, Germany), which has shown to be an effective and reliable gaseous exchange instrument [@R02-2018-0071-0023] . All parameters were calculated as the average of the two highest consecutive 30-s measurements as a result of the tests' short duration (5--8 min) in comparison to traditional VO ~2~ max tests (8--12 min). The gas analyzer was calibrated before each testing day using certified gases (15% O ~2~ , 5% CO ~2~ ) and the flow turbine was calibrated before each individual time trial using a 3 L syringe as previously described [@R02-2018-0071-0010] . Time to completion (s), average power (W), relative and absolute VO ~2~ peak (mL·min ^−1^ ·kg ^−1^ and L·min ^−1^ , respectively), and respiratory exchange ratio (RER) were all measured.

Lactate, heart rate and perceived exertion
------------------------------------------

Lactate (LactatePro, Arkray, Kyoto, Japan) was collected using a fingertip capillary blood sample pre-warm-up as well as immediately post and 5-min post each time trial to attempt to capture the peak reading. Similar collection times have been used by other researchers [@R02-2018-0071-0024] . Heart rate was measured continuously (Polar, Kempele, Finland) during the time trial and a finishing heart rate (bpm) was measured. Immediately upon completion of the time trial each athlete provided a rating of perceived exertion (RPE) and this was reported individually to prevent bias [@R02-2018-0071-0005] ( [Table 2](#TB02-2018-0071-0002){ref-type="table"} ).

###### 

**Table 2** Heart rate, RER, RPE and lactate concentrations at the conclusion of the 4000-m time trial.

  Group                          Sham        Once-a-day   Twice-a-day                                                               
  ------------------------------ ----------- ------------ ------------- ----------- ----------- ----------- ----------- ----------- -----------
  Heart rate (bpm)               178±11      178±11       173±11        181±18      182±18      182±17      184±10      184±10      180±13
  RER                            1.08±0.05   1.11±0.05    1.07±0.04     1.13±0.05   1.11±0.04   1.09±0.02   1.14±0.06   1.18±0.05   1.13±0.07
  RPE                            16.9±1.5    16.4±1.1     16.9±1.4      17.1±1.8    17.5±1.3    16.9±1.3    17.8±1.4    17.0±1.5    15.5±2.3
  Blood lactate (mmol/L ^−1^ )   11.0±3.7    9.8±2.9      11.0±2.3      11.3±4.1    12.2±2.4    12.4±1.3    13.6±2.1    13.2±2.9    12.8±2.7
  Blood lactate (% change)       872±422     994±363      929±280       862±410     1038±450    1025±408    1200±460    965±380     1051±193

Values are mean±SD;

RER=respiratory exchange ratio, RPE=rating of perceived exertion

Ischemic preconditioning application
------------------------------------

The protocols commenced the morning following the first 4000-m time trial. With the subject in the supine position, a manual inflatable cuff (East Shore Medical Supply Inc., New York, USA) was positioned unilaterally on the upper leg where the adductor longus muscle attaches to the inguinal ligament. A line was drawn with a permanent marker perpendicular to the femur from this junction to ensure the inflatable cuff was positioned in exactly the same position each day. Athletes allocated to the once-a-day treatment (40 min) received 4×5 min occlusion/5 min reperfusion of IP (220 mmHg) per leg [@R02-2018-0071-0019] in the morning followed by 4×5 min occlusion/5 min reperfusion episodes of sham treatment (20 mmHg) per leg in the evening. The pressures chosen have been commonly used in IP research protocols [@R02-2018-0071-0006] [@R02-2018-0071-0019] . Allocation to the twice-a-day group (80 min) required the same 220 mmHg treatment as the once-a-day group but was administered both in the morning and evening. The placebo group (0 min at 220 mmHg) was administered the same sham treatment (20 mmHg) as the once-a-day group but in the morning and evening. Alternating unilateral occlusion was achieved by alternating the inflatable cuff from the left to the right leg (when one leg received reperfusion, the other was under ischemia) to ensure the volume of tissue occluded was great enough to elicit a physiological response [@R02-2018-0071-0017] . Each athlete completed their allocated treatment at approximately the same time of day for seven consecutive days at their own residence, and correct administration was provided by the research team following the first experimental day.

Statistical analyses
--------------------

The effect of repeated IP duration on the change in aerobic capacity parameters was tested in a linear mixed-effects model fitted with restricted maximum likelihood, conducted in the lme4 package [@R02-2018-0071-0003] , in R version 3.1.1. In conjunction with Cohen's effect sizes ( *d* ), P values were calculated using Satterthwaite\'s method of denominator synthesis, conducted in the lmerTest package [@R02-2018-0071-0018] for R. Each aerobic capacity parameter was analyzed as the response variable in a separate model. Athlete identity was included as crossed random effects to account for the non-independence of marker measures from each athlete. All data is presented as mean±SEM. Statistical significance was set at p\<0.05.

Results
=======

Repeated IP did not result in any change in 4000-m time-trial time ( [Fig. 2a](#FI02-2018-0071-0002){ref-type="fig"} ) 24 h and seven days post-treatment for the sham (p=0.2 to 0.5, *d* =0.05 to 0.22) and once-a-day (p=0.3 to 0.6, *d* =0.06 to 0.09) protocols. It did however result in a significant but trivial increase in time-trial time (performance detriment) immediately post (p=0.03, *d* =0.17) and a non-significant trivial change (performance detriment) seven days post (p=0.07, *d* =0.14) for the twice-a-day IP group. Individual differences did exist within each of the treatment groups for the 4000-m time-trial time. However, no differences existed between or within the three treatment groups for finishing heart rate, RER and RPE (p\>0.05, *d* \<0.2) following the 4000-m time trials.

![4000-m time-trial time ( **a** ) and average power ( **b** ) for each of the repeated ischemic preconditioning protocols. (Sham=0 min/day at 220 mmHg; once-a-day=40 min/day at 220 mmHg; twice-a-day=80 min/day at 220 mmHg). Data are mean + SEM. \* p\<0.05 for the within-group change from the pretest.](10-1055-a-0639-5035-i02-2018-0071-0002){#FI02-2018-0071-0002}

There was also no difference in the average power ( [Fig. 2b](#FI02-2018-0071-0002){ref-type="fig"} ) for the sham (p=0.3 to 0.4, *d* =0.07 to 0.1) and once-a-day (p=0.4 to 0.9, *d* =0.0 to 0.15) IP protocols immediately and seven days post IP but a significant small decrease (p=0.03 to 0.04, *d* =0.23) for the twice-a-day IP protocol (performance detriment).

There was a trend (p=0.07, *d* =0.1) toward an increase in relative VO ~2~ peak ( [Fig. 3a](#FI02-2018-0071-0003){ref-type="fig"} ) for the sham group immediately following the repeated IP protocol and a significant small increase seven days post (p=0.02, *d* =0.24), which resulted in a significant small increase (p=0.01, *d* =0.27) in absolute VO ~2~ peak ( [Fig. 3b](#FI02-2018-0071-0003){ref-type="fig"} ). No differences existed for relative and absolute VO ~2~ peak for the once-a-day (p\>0.05, *d* \<0.1) and twice-a-day (p\>0.05, *d* \<0.1) IP protocols at any time point during the time trials.

![Relative ( **a** ) and absolute ( **b** ) VO ~2~ peak following the 4000-m time-trial times for the repeated ischemic preconditioning protocols. (Sham=0 min/day at 220 mmHg; once-a-day=40 min/day at 220 mmHg; twice-a-day=80 min/day at 220 mmHg). Data are mean + SEM. \* p\<0.05 for the within-group change from the pretest.](10-1055-a-0639-5035-i02-2018-0071-0003){#FI02-2018-0071-0003}

No statistical difference existed between or within the three treatment groups for absolute and percentage changes in blood lactate concentrations (p\>0.05, *d* \<0.1) following each of the 4000-m time trials.

Discussion
==========

This study is unique because it is the first to investigate the benefit of doubling the ischemia-reperfusion tissue exposure in moderately trained athletes. However, in contrast to previous findings [@R02-2018-0071-0019] [@R02-2018-0071-0008] [@R02-2018-0071-0009] but in agreement with other researchers [@R02-2018-0071-0024] [@R02-2018-0071-0027] , there was no improvement in VO ~2~ peak or cycling performance for the groups administered IP. This raises the possibility of responder versus non-responders to IP [@R02-2018-0071-0014] . Indeed, if we look at individual responses within the groups of the present study, we find that the once-a-day and twice-a-day groups did have two and three responders, respectively. Hence, when the results are grouped with the non-responders in each group, overall group changes may be masked. Sex has also been suggested to influence the success rate of IP investigations, with IP less effective in female populations [@R02-2018-0071-0011] . There were three and two females in the once- and twice-a-day groups, respectively, thereby increasing the difficulty of seeing positive changes in each of these groups.

A previous IP study undertaken [@R02-2018-0071-0019] used recreationally active participants, many of whom were unfamiliar with cycling, and any form of training stimulus would likely result in functional adaptation. The moderately trained cyclists of the present investigation competed at a national standard in their respective age categories, and were actively training on average 10.3±3.6 h a week. The 'ceiling effect' may have an influence here with these athletes having less scope to improve, and indeed may require a larger IP stimulus to show even a small adaptation gain as previously suggested [@R02-2018-0071-0013] . Interestingly, other studies that used IP acutely (single session) have seen performance improvements in sports such as cycling [@R02-2018-0071-0009] , Olympic level swimming [@R02-2018-0071-0015] and running [@R02-2018-0071-0001] , which indicates other factors may be have contributed to the lack of the present response.

Another possibility is the IP combined with the athletes current training phase resulted in too great a stress and subsequent maladaptation. The sham group showed significant albeit small gains in both relative and absolute VO ~2~ peak in the retest 7 days post, whereas the IP intervention groups showed no change. Evidence suggests, however, that alterations in key inflammatory cytokines and modulation of oxidative mechanisms are partially responsible for the protective effect of acute and repeated IP [@R02-2018-0071-0004] . The combined effect of these changes in combination with exercise-induced stress may lead to a physiological environment that inhibits a positive training adaptation through development of negative stimulus. Indeed, application of a repeated IP protocol has been shown to negate vascular protection in an animal model [@R02-2018-0071-0007] .

Rather than using a maximal exercise test, the current study aimed to provide more applicable event-specific advice by quantifying the potential performance benefit of using a set cycling event, which in this case equated to a 4000-m time-trial distance. Although the participants were competitive track cyclists, several limitations may have contributed to the non-significant group differences. During the time trials, minimal feedback was given to the athletes, yet in competition these athletes may rely on many sources of external feedback including sideline coaches, clocks, and even their opposition to optimize their pacing strategy. It has been previously recommended that athletes need time to adjust to the perceptual experience of endurance time trials [@R02-2018-0071-0029] . The current finding is in agreement with a study by Tocco et al. (2015) conducted on runners that found IP did not improve self-paced exercise performance [@R02-2018-0071-0032] .

Our study demonstrated that repeated IP does not improve 4000-m time-trial performance, irrespective of the dose and the number of days after the intervention the cyclist is tested. Previously in our lab, we observed that repeated IP improves lactate clearance; however on this occasion there was no change. It is possible that a positive lactate clearance effect was attenuated in these conditioned athletes when training is combined with the repeated IP dose. Coaches may suggest that IP could provide a useful training stimulus even for those highly conditioned in certain situations or during certain phases of training, such as returning from injury or in the peaking phase before a major competition when the training volume is dramatically reduced. However, studies are required to confirm any potential gains of IP used repeatedly as a training tool. Until then, the validity of using IP as a training tool to enhance athletic performance is questionable. Any future studies should look to determine the optimal dosage, especially for individuals, by manipulating three main variables: the number of occlusion bouts per session, the duration of each occlusion repetition and the number of days over which the protocol is performed. Finally, new markers of adaptation should also be investigated to allow monitoring of IP progress within any intervention phase.

Although IP used as a training tool through repeated daily administration has previously been shown successful in inducing functional changes that have the potential to improve sporting performance, further research is required to optimize the required dosage. Individualization and timing of the dose may be required to maximize adaptation and subsequent sporting performance.
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